Prostate cancer diagnosis: Present and future

被引：1

作者：

Baseilhac, P. ^{[1
]}

Rouviere, O. ^{[1
,2
,3
,4
]}

机构：

[1] Hop Edouard Herriot, Serv Imageire, Hosp Civils Lyon, Lyon, France

[2] Univ Lyon 1, Lyon, France

[3] Inserm U1032, LabTau, Lyon, France

[4] Hop Edouard Herriot, Serv Imagerie, Pavillon B,5 Pl Arsonval, F-69003 Lyon, France

来源：

MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE | 2023年 / 47卷 / 05期

关键词：

Prostate cancer; Magnetic Resonance Imaging; Diagnostic; Classifications; SIOG GUIDELINES; LOCAL TREATMENT; DATA SYSTEM; ANTIGEN; BIOPSY; OVERDIAGNOSIS; MORTALITY; MRI; MEN; PERFORMANCE;

D O I：

10.1016/j.mednuc.2023.07.006

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

MRI has become a central element in prostate cancer diagnosis because it can improve the detection of aggressive tumours by guiding biopsies. It is also increasingly used, in conjunction with PSA density, to select patients for biopsies. Systematic sextant biopsies, which are still recommended in addition to targeted biopsies, could gradually disappear and be replaced by more extensive sampling of MRI targets and their surroundings (peri-lesional biopsies). Organized prostate cancer screening, which is not currently recommended, could be proposed in the future if it can be shown that MRI, in combination with PSA and other simple biomarkers, can maintain good detection of aggressive cancers while limiting overdiagnosis of indolent forms.(c) 2023 Elsevier Masson SAS. All rights reserved.

引用

页码：233 / 240

页数：8

共 85 条

[1]

[Anonymous], 2013, Cancer Statistics Review, 1975-2013-Previous Version-SEER Cancer Statistics Review

[2] Contrast-medium administration for prostate MRI: yes! Contrast-medium administration can be abandoned [J].

Asbach, Patrick .

EUROPEAN RADIOLOGY, 2023, 33 (12) :8413-8414

[3] Biology of prostate-specific antigen [J].

Balk, SP ;

Ko, YJ ;

Bubley, GJ .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (02) :383-391

[4] Prostate Cancer Risk Calculators for Healthy Populations: Systematic Review [J].

Bandala-Jacques, Antonio ;

Esquivel, Kevin Daniel Castellanos ;

Perez-Hurtado, Fernanda ;

Hernandez-Silva, Cristobal ;

Reynoso-Noveron, Nancy .

JMIR CANCER, 2021, 7 (03)

[5] ESUR prostate MR guidelines 2012 [J].

Barentsz, Jelle O. ;

Richenberg, Jonathan ;

Clements, Richard ;

Choyke, Peter ;

Verma, Sadhna ;

Villeirs, Geert ;

Rouviere, Olivier ;

Logager, Vibeke ;

Futterer, Jurgen J. .

EUROPEAN RADIOLOGY, 2012, 22 (04) :746-757

[6] Targeted biopsy of the prostate: does this result in improvement in detection of high-grade cancer or the occurrence of the Will Rogers phenomenon? [J].

Bass, Edward J. ;

Orczyk, Clement ;

Grey, Alistair ;

Freeman, Alex ;

Jameson, Charles ;

Punwani, Shonit ;

Ramachandran, Navin ;

Allen, Clare ;

Emberton, Mark ;

Ahmed, Hashim U. .

BJU INTERNATIONAL, 2019, 124 (04) :643-648

[7] Evaluation of the Prostate Imaging Reporting and Data System for the Detection of Prostate Cancer by the Results of Targeted Biopsy of the Prostate [J].

Baur, Alexander D. J. ;

Maxeiner, Andreas ;

Franiel, Tobias ;

Kilic, Ergin ;

Huppertz, Alexander ;

Schwenke, Carsten ;

Hamm, Bernd ;

Durmus, Tahir .

INVESTIGATIVE RADIOLOGY, 2014, 49 (06) :411-420

[8] Prevalence of incidental prostate cancer: A systematic review of autopsy studies [J].

Bell, Katy J. L. ;

Del Mar, Chris ;

Wright, Gordon ;

Dickinson, James ;

Glasziou, Paul .

INTERNATIONAL JOURNAL OF CANCER, 2015, 137 (07) :1749-1757

[9] Risk-based MRI-directed diagnostic pathway outperforms non-risk-based pathways in suspected prostate cancer biopsy-naive men: a large cohort validation study [J].

Bittencourt, Leonardo Kayat ;

Guricova, Karolina ;

Zucker, Isaac ;

Durieux, Jared C. ;

Schoots, Ivo G. .

EUROPEAN RADIOLOGY, 2022, 32 (04) :2330-2339

[10]

Brierley JD., 2017, TNM CLASSIFICATION M

← 1 2 3 4 5 6 7 8 9 →